데이터를 보충하는 중입니다. 잠시 후 페이지를 새로 고치면 최신 내용을 볼 수 있습니다
기본 정보
- CAS
259793-96-9- 표준 SMILES
NC(=O)c1nc(F)c[nH]c1=O- InChIKey
ZCGNOVWYSGBHAU-UHFFFAOYSA-N- 분자식
- C5H4FN3O2
- 평균 분자량
- 157.104 g/mol
- 단동위원소 질량
- 157.02875459
이름 및 식별자
- 우선 이름
- 6-Fluoro-3-hydroxypyrazine-2-carboxamide
- IUPAC
- 6-Fluoro-3-hydroxypyrazine-2-carboxamide
- 현지명
- 피라진카르복스아미드,6-플루오로-3,4-디히드로-3-옥소-(9CI)
- 영어명
- Favipiravir
- 분자식
- C5H4FN3O2
- 분자량
- 157.1
이름 및 동의어
피라진카르복스아미드,6-플루오로-3,4-디히드로-3-옥소-(9CI)6-Fluoro-3-hydroxypyrazine-2-carboxamideT-7056-fluoro-3,4-dihydro-3-oxo-PyrazinecarboxamideAviganFavipiravi6-fluoro-3,4-dihydro-3-oxo- (9CI)6-Fluoro-3-hydroxy-2-pyrazinecarboxamidePyrazinecarboxamide, 6-fluoro-3,4-dihydro-3-oxo- (9CI)Farapiwe3-Dithian
데이터베이스 식별자
- CAS
259793-96-9- PubChem CID
- 492405
- DTXSID
DTXSID60948878- ChEMBL
CHEMBL221722- ChEBI
CHEBI:134722- UNII
- EW5GL2X7E0
- EC Number
- 856-840-0
- Nikkaji
- J1.636.682J
물성
물리화학적 성질
- 녹는점
- 151 °C · >151°C (dec.)
- 밀도
- 1.78 · 1.78±0.1 g/cm3(Predicted)
- 저장 조건
- 2 · under inert gas (nitrogen or Argon) at 2-8°C
- 용해도
- DMSO(30mg/mL), 물(가온 시 12mg/mL)에 용해됨
- 산도 계수 (pKa)
- 8.77 · 8.77±0.60(Predicted)
- 물리적 상태
- 고체
- 색상
- 회백색
- 안정성
- 1 · 제공된 대로 구매일로부터 1년 동안 안정적입니다. DMSO 또는 물에 용해된 용액은 -20°에서 최대 3개월 동안 보관할 수 있습니다.
- InChI
- InChI=1S/C5H4FN3O2/c6-2-1-8-5(11)3(9-2)4(7)10/h1H,(H2,7,10)(H,8,11)
- InChIKey
- ZCGNOVWYSGBHAU-UHFFFAOYSA-N
- SMILES
- C1(C(N)=O)=NC(F)=CNC1=O
안전 및 규제
안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.
안전 데이터
- wgk
- WGK 3
- Hazard Classifications
- Muta. 2Repr. 2
- 스토리지 클래스
- 11 - Combustible Solids
화학 및 산업
응용 분야
개요Favipiravir, 6-fluoro-3-hydroxypyrazine-2-carboxamide, is a new broad-spectrum antiviral drug targeting RNA-dependent RNA polymerase (RdRp) developed by Japan's Toyama Chemical Pharmaceutical Company. It was approved for marketing in Japan in March 2014 for the treatment of new and recurrent influenza. During the outbreak of the new coronavirus, the results of the Phase I clinical study of the drug published in March 2020 showed that the drug may have the effect of speeding up virus clearance to alleviate the progress of new coronavirus pneumonia.
역사Favipiravir was originally developed in the late 1990s by a company that was later purchased by the Japanese firm Fujifilm as part of its transition from the photo business to healthcare. After being tested against a range of viruses, the drug was approved in Japan in 2014 for emergency use against flu epidemics or to treat new strains of influenza.
용도Favipiravir is used for the treatment of advanced Ebola virus infection in a small animal model. It suppressed the replication of Zaire Ebola virus and prevented a lethal outcome in 100% of the animals. Based on the studies, Favipiravir can be a candidate for the treatment of Ebola hemorrhagic fever. Favipiravir can be used for antiviral treatment of influenza A and B. Studies have shown that in addition to influenza virus, the drug also exhibits good antiviral activity against a variety of RNA viruses, such as Ebola virus, arena virus, Bunia virus, rabies virus and now COVID-19.
상·하류 제품 정보
상류 원료
관련 반응
0건
현재 필터 조건에 해당하는 반응 기록이 없습니다.
화합물 노트
불러오는 중…